Background: Erlotinib is proven to prolong survival, delay symptom progression and improve
quality of life for pts with advanced NSCLC (Shepherd et al. N Engl J Med 2005; 353: 123 …

Aims: The efficacy of erlotinib (Tarceva, Roche Products, Dee Why, Australia) has been
demonstrated in patients with advanced non‐small‐cell lung cancer (NSCLC). Tarceva lung …

Introduction: The primary objective of this study was to compare the response rates of
elderly, chemonaive patients with advanced non-small cell lung cancer (NSCLC) treated …

Introduction: Erlotinib is an epidermal growth factor receptor tyrosine kinase inhibitor that
significantly increases survival for patients with previously treated advanced non-small cell …

7645 Background: In patients (pts) with relapsed NSCLC, erlotinib 150 mg/d significantly
prolonged survival, delayed symptom progression, and improved quality of life versus …

Abstract Learning Objectives After completing this course, the reader will be able to:
Evaluate the relationship between EGFR mutation status and clinical outcomes reported in …

Background: A randomized trial carried out by Shepherd et al. in patients with advanced or
metastatic non-small-cell lung cancer showed statistically significant benefit of erlotinib over …

Background: Erlotinib is approved as treatment for metastatic non-small-cell lung cancer
(NSCLC), following failure of initial therapy. Studies to define patients that derive maximal …

Background: Erlotinib is a standard of treatment for metastatic non-small-cell lung cancer
after failure of initial therapy. Patient selection based on clinical factors is under discussion …

Background Many patients with advanced non-small-cell lung cancer (NSCLC) receive only
active supportive care because of poor performance status or presence of several …